Product news

Share this article:
The FDA has broadened the US indication for Novartis' Reclast (zoledronic acid) once-yearly injection to include the prevention of new clinical fractures in patients who have recently had a low-trauma hip fracture. The FDA decision is based on safety and efficacy data from the “Recurrent Fracture Trial,” published in The New England Journal of Medicine. Trial results showed a 35% reduction in the risk of new clinical fractures in patients treated with Reclast, Novartis said.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs


Reimagining healthcare? We want to hear about it.
 
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters

MM&M inVISION

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.